Category Archives: Stem Cell Research

Cancer Stem Cells (CSCs) Market

DataIntelo, 08-04-2020: The research report on the Cancer Stem Cells (CSCs) Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data and compared it with the changing market situations. The report covers all the necessary information required by new entrants as well as the existing players to gain deeper insight.

Furthermore, the statistical survey in the report focuses on product specifications, costs, production capacities, marketing channels, and market players. Upstream raw materials, downstream demand analysis, and a list of end-user industries have been studied systematically, along with the suppliers in this market. The product flow and distribution channel have also been presented in this research report.

Get a PDF Copy of the Sample Report for Free @ https://dataintelo.com/request-sample/?reportId=116862

The Major Manufacturers Covered in this Report:JanssenQiagenAdvanced Cell DiagnosticsApoCellBiofluidicaClearbridge BiomedicsCytoTrackCelseeFluxionGilupiCynvenioOn-chipYZY BioBioViewCreatv MicroTechFluidigmIkonisysAdnaGenIVDiagnosticsMiltenyi BiotecAviva Biosciences CorporationScreenCellSilicon Biosystems

The Research Study Focuses on:

By Types:CellSearchOthers

By Applications:Breast Cancer Diagnosis and TreatmentProstate Cancer Diagnosis and TreatmentColorectal Cancer Diagnosis and TreatmentLung Cancer Diagnosis and TreatmentOther Cancers Diagnosis and Treatment

By Regions:

To get this report at incredible Discounts, visit @ https://dataintelo.com/ask-for-discount/?reportId=116862

The Cancer Stem Cells (CSCs) Market Report Consists of the Following Points:

Make an Inquiry of the Cancer Stem Cells (CSCs) Market Report @ https://dataintelo.com/enquiry-before-buying/?reportId=116862

In conclusion, the Cancer Stem Cells (CSCs) Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rate, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://dataintelo.com

Excerpt from:
Cancer Stem Cells (CSCs) Market Size, Share & Trends Analysis Report By Product Types, And Applications Forecast To 2026 - Science In Me

The Global Stem Cell Services Market analysis report published on IndustryGrowthInsights.com is a detailed study of market size, share and dynamics covered in XX pages and is an illustrative sample demonstrating market trends. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It covers the entire market with an in-depth study on revenue growth and profitability. The report also delivers on key players along with strategic standpoint pertaining to price and promotion.

Get FREE Exclusive PDF Sample Copy of This Report: https://industrygrowthinsights.com/request-sample/?reportId=172092

The Global Stem Cell Services Market report entails a comprehensive database on future market estimation based on historical data analysis. It enables the clients with quantified data for current market perusal. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and regional analysis. Listed out are key players, major collaborations, merger & acquisitions along with upcoming and trending innovation. Business policies are reviewed from the techno-commercial perspective demonstrating better results. The report contains granular information & analysis pertaining to the Global Stem Cell Services Market size, share, growth, trends, segment and forecasts from 2020-2026.

With an all-round approach for data accumulation, the market scenarios comprise major players, cost and pricing operating in the specific geography/ies. Statistical surveying used are SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics. Graphs are clearly used to support the data format for clear understanding of facts and figures.

Customize Report and Inquiry for The Stem Cell Services Market Report: https://industrygrowthinsights.com/enquiry-before-buying/?reportId=172092

Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Primary research, interviews, news sources and information booths have made the report precise having valuable data. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

The report segments the Global Stem Cell Services Market as:Global Stem Cell Services Market Size & Share, by Regions

Global Stem Cell Services Market Size & Share, by ProductsCustomize ServiceStem Cell DifferentiationAssay DevelopmentScreeningOthersStem Cell Service

Global Stem Cell Services Market Size & Share, ApplicationsHospitalResearch InstituteOthers

Key PlayersParagon BioservicesAPEX BiologixVcanBioCryo-cellCrioestaminalLifeCellViaCordPepro TechHealth BabyStem Cell Service

Avail the Discount on this Report @ https://industrygrowthinsights.com/ask-for-discount/?reportId=172092

IndustryGrowthInsights offers attractive discounts on customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About IndustryGrowthInsights:INDUSTRYGROWTHINSIGHTS has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario, CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://IndustryGrowthInsights.com

Visit link:
Stem Cell Services Market 2020 Size By Product Types, End-Users, Regional Outlook, Growth Potential, Price Trends And Forecast To 2026 | Industry...

A study published in STEM CELLS Translational Medicine, by researchers at The Baker Institute for Animal Health, at Cornell's College of Veterinary Medicine, demonstrates for the first time that mesenchymal stromal cells (MSCs) are an effective weapon against bacteria in biofilm.

DURHAM, N.C., March 26, 2020 /PRNewswire-PRWeb/ -- Researchers have potentially made a breakthrough in the war on antibiotic-resistant superbugs including MRSA, which kills an estimated 20,000 people in the United States alone each year with a new discovery whose details are published today in STEM CELLS Translational Medicine. The study, by researchers at The Baker Institute for Animal Health, at Cornell's College of Veterinary Medicine, demonstrates for the first time that mesenchymal stromal cells (MSCs) are an effective weapon against bacteria in biofilm.

Biofilms are thin, slimy films made up of bacteria that can attach to skin wounds, teeth and other surfaces, creating the opportunity for infections to flourish. These highly structured cellular communities offer bacteria shelter from harmful factors, helping them resist antibiotics, mutate rapidly and evade the immune system.

"MSCs help kill the bacteria through the secretion of enzymes, called proteases, that break the peptide bonds of proteins and cause biofilm to destabilize. This in turn increases the effectiveness of antibiotics that previously weren't working, as the bacteria are no longer being protected by the biofilm," explained Gerlinde R. Van de Walle, DVM, Ph.D., who led the study along with Charlotte Marx, DVM, Ph.D.

Other recent studies, including one by the Cornell team, have shown that MSCs can inhibit the growth of bacteria associated with chronic infections by secreting antimicrobial peptides. "But these studies were conducted primarily on planktonic bacteria, which are individually floating bacteria cells. Thus, information on the effects on biofilms was largely lacking," Dr. Marx said.

The current study explores how MSC secretome, delivered as conditioned medium, performs against various wound-related bacterial pathogens. It also looks at the mechanisms that affect bacterial biofilms. The experiments were performed in vitro, using equine MSC. "We use equine MSC in our work since the horse represents a physiologically relevant model for human wound healing and offers a readily translatable model for MSC therapies in humans," Dr. Van de Walle explained.

The researchers began by showing that equine MSC secretome inhibits the growth of four types of planktonic bacteria that commonly colonize skin wounds. Encouraged by the results, they next sought to determine the effect of the MSC secretome on these same bacterial strains in biofilms, which is the predominant way bacteria invade wounds. They looked at how the MSCs affected biofilm formation, then repeated the experiments on biofilms that were already established. Finally, they turned their attention to the bacteria strain responsible for MRSA.

Dr. Marx reported the results. "Our salient findings," she said, "were that factors secreted by equine MSC impaired both planktonic and biofilms including MRSA as well as disrupted mature biofilms generated by these bacteria. Importantly, we found that these effects resulted from a protease-dependent mechanism."

Dr. Van de Walle added, "We also found that MSC-secreted factors allowed previously ineffective antibiotic treatments to become more effective at reducing bacterial survival. In light of the rise of antibiotic-resistant bacterial strains as an increasing global health threat, our findings provide the rationale for using the MSC secretome as a complementary treatment for bacterial infections."

"Outcomes from this study highlight for the first time that the secretome from mesenchymal stem cells significantly reduces the formation of bacterial infections, including the antibiotic resistant MRSA," said Anthony Atala, M.D., Editor-in-Chief of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine. "Antibiotic resistance has long been a concern and this research highlights some promising new tactics."

###

The full article, "The mesenchymal stromal cell (MSC) secretome impairs methicillin-resistant S. aureus (MRSA) biofilms via cysteine protease activity in the equine model," can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/sctm.19-0333.

Story continues

About STEM CELLS Translational Medicine: STEM CELLS Translational Medicine (SCTM), co-published by AlphaMed Press and Wiley, is a monthly peer-reviewed publication dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices. SCTM is the official journal partner of Regenerative Medicine Foundation.

About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes two other internationally renowned peer-reviewed journals: STEM CELLS (http://www.StemCells.com), celebrating its 38th year, is the world's first journal devoted to this fast paced field of research. The Oncologist (http://www.TheOncologist.com), also a monthly peer-reviewed publication, entering its 25th year, is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. All three journals are premier periodicals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines.

About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.

About Regenerative Medicine Foundation (RMF): The non-profit Regenerative Medicine Foundation fosters strategic collaborations to accelerate the development of regenerative medicine to improve health and deliver cures. RMF pursues its mission by producing its flagship World Stem Cell Summit, honouring leaders through the Stem Cell and Regenerative Medicine Action Awards, and promoting educational initiatives.

SOURCE STEM CELLS

More here:
Study offers potential breakthrough in the war on antibiotic-resistant superbugs - Yahoo Finance

During this process the cells not only shed any memories of their previous identities, but they revert to a younger state. They accomplish this transformation by wiping their DNA clean of the molecular tags that not only differentiate, say, a skin cell from a heart muscle cell, but of other tags that accumulate as a cell ages.

Recently researchers have begun to wonder whether exposing the adult cells to Yamanaka proteins for days rather than weeks could trigger this youthful reversion without inducing full-on pluripotency. In fact, researchers at the Salk Institute for Biological Studies found in 2016 that briefly expressing the four Yamanaka factors in mice with a form of premature aging extended the animals life span by about 20%. But it wasnt clear whether this approach would work in humans.

Sarkar and Sebastiano wondered whether old human cells would respond in a similar fashion, and whether the response would be limited to just a few cell types or generalizable for many tissues. They devised a way to use genetic material called messenger RNA to temporarily express six reprogramming factors the four Yamanaka factors plus two additional proteins in human skin and blood vessel cells. Messenger RNA rapidly degrades in cells, allowing the researchers to tightly control the duration of the signal.

The researchers then compared the gene-expression patterns of treated cells and control cells, both obtained from elderly adults, with those of untreated cells from younger people. They found that cells from elderly people exhibited signs of aging reversal after just four days of exposure to the reprogramming factors. Whereas untreated elderly cells expressed higher levels of genes associated with known aging pathways, treated elderly cells more closely resembled younger cells in their patterns of gene expression.

When the researchers studied the patterns of aging-associated chemical tags called methyl groups, which serve as an indicator of a cells chronological age, they found that the treated cells appeared to be about 1 to 3 years younger on average than untreated cells from elderly people, with peaks of 3 years (in skin cells) and 7 years (in cells that line blood vessels).

Next they compared several hallmarks of aging including how cells sense nutrients, metabolize compounds to create energy and dispose of cellular trash among cells from young people, treated cells from old people and untreated cells from old people.

We saw a dramatic rejuvenation across all hallmarks but one in all the cell types tested, Sebastiano said. But our last and most important experiment was done on muscle stem cells. Although they are naturally endowed with the ability to self-renew, this capacity wanes with age. We wondered, Can we also rejuvenate stem cells and have a long-term effect?

When the researchers transplanted old mouse muscle stem cells that had been treated back into elderly mice, the animals regained the muscle strength of younger mice, they found.

Finally, the researchers isolated cells from the cartilage of people with and without osteoarthritis. They found that the temporary exposure of the osteoarthritic cells to the reprogramming factors reduced the secretion of inflammatory molecules and improved the cells ability to divide and function.

The researchers are now optimizing the panel of reprogramming proteins needed to rejuvenate human cells and are exploring the possibility of treating cells or tissues without removing them from the body.

Although much more work needs to be done, we are hopeful that we may one day have the opportunity to reboot entire tissues, Sebastiano said. But first we want to make sure that this is rigorously tested in the lab and found to be safe.

Other Stanford co-authors are former postdoctoral scholar Marco Quarta, PhD; postdoctoral scholar Shravani Mukherjee, PhD; graduate student Alex Colville; research assistants Patrick Paine, Linda Doan and Christopher Tran; Constance Chu, MD, professor of orthopaedic surgery; Stanley Qi, PhD, assistant professor of bioengineering and of chemical and systems biology; and Nidhi Bhutani, PhD, associate professor of orthopaedic surgery.

Researchers from the Veterans Affairs Palo Alto Health Care System, the University of California-Los Angeles and the Molecular Medicine Research Institute in Sunnyvale, California, also contributed to the study.

The research was supported by the National Institutes of Health (grants R01 AR070865, R01 AR070864, P01 AG036695, R01 AG23806, R01 AG057433 and R01 AG047820), the Glenn Foundation for Medical Research, the American Federation for Aging Research and the Department of Veterans Affairs.

Sarkar, Quarta and Sebastiano are co-founders of the startup Turn Biotechnologies, a company that is applying the technology described in the paper to treat aging-associated conditions. Rando is a member of the scientific advisory board.

Here is the original post:
Old human cells rejuvenated with stem cell technology - Stanford Medical Center Report

For the first time, scientists have reprogrammed cells from a 114-year-old woman into induced pluripotent stem cells (iPS cells), a move which they describe as a significant step toward understanding"the underlying mechanisms of extreme longevity and disease resistance."

iPS cells are adult cells that have been genetically reprogrammed into an embryonic stem cell-like state and are able to give rise to any of the specialized cell types of the body, whether its neurons, blood cells, or heart cells.

Until this new project, researchers werent even certain whether they could create viable iPS cellsfrom someone so elderly, let alone a supercentenarian. Now they have shown it's possible to effectively make these aged cells resemble young pluripotent cells, the researchers believe they might have made a step towards the reversal of cellular aging.

"We set out to answer a big question: Can you reprogram cells this old?" Evan Snyder, stem cell researcher at Sanford Burnham Prebys Medical Discovery Institute in California, said in a statement.

"Now we have shown it can be done, and we have a valuable tool for finding the genes and other factors that slow down the aging process."

Reporting in the journal Biochemical and Biophysical Research Communications, researchers harnessed iPS cells from the blood cells of a 114-year-old woman, a healthy 43-year-old person, and an 8-year-old child with a rare genetic condition characterized by the rapid aging in childhood. These iPS cells were then turned into mesenchymal stem cells, cells that help maintain and repair the body's structural tissues differentiating into bone, cartilage, muscle, or fat cells.

Remarkably, the cells produced from the supercentenarian transformed just as easily as the others. They also noted the supercentenarian-derived stem cells appeared to have reset their telomeres.

Telomeresarethe protective caps on the end of a chromosome. Since they shorten each time a cell copies itself, they also get shorter as we age and eventually stop functioning properly. Thispersistent shortening allows researchers to use telomeres as a kind of aging clock in every cell.Interestingly, the stem cells from the supercentenarian showed no indication of this aging. They had effectively reset the clock on the cells from114 years to zero.

To dive deeper into this discovery, the researchers hope to compare body cells derived from the healthy iPSCs and supercentenarian iPSCs. The researchers could also start to use the supercentenarian cells to understand why certain people have such long lives compared to others.

Why do supercentenarians age so slowly? We are now set to answer that question in a way no one has been able to before, said Snyder.

Read more from the original source:
Scientists Have 'Reset' The Cellular Age Of Cells Taken From A 114-Year-Old Woman - IFLScience

New York, United States, March 20, 2020 (GLOBE NEWSWIRE) -- The global recombinant cell culture supplements market, valued at US$ 320 Mn by the end of 2018, will grow at a steady rate from 2029-2029. The market players are investing in research and development activities to create new vaccines. They are targeting developing nations such as India and China for the same to benefit from their favorable government policies regarding foreign investments. Manufacturers are enhancing their presence across different distribution networks to market their products.

Recombinant Cell Culture Supplements Market: Key Takeaways

Request for sample Report: https://www.persistencemarketresearch.com/samples/31310

Recombinant Cell Culture Supplements Market: Key Growth Drivers

Recombinant Cell Culture Supplements Market: Key Restraints

The complete recombinant cell culture supplements market report with detailed market segmentation, 200 illustrative figures, and 63 data tables spread across 306 pages onhttps://www.persistencemarketresearch.com/methodology/31310

Recombinant Cell Culture Supplements Market: Competition LandscapeThe competition landscape is highly intense where every player is expanding its product portfolio to stay at the forefront in the market. established players are acquiring regional players to strengthen their regional footprint. For instance, Thermo Fisher Scientific acquired the bio-processing business of Becton Dickinson to expand its product portfolio.

Get Persistence Market Researchs Detailed Coverage OnCell Culture Media Market: Get intensive information on the global cell culture media market with vital updates on market growth drivers, changing market dynamics, existing market challenges, government policies and laws, segmental market forecast and key market strategies prominent players.

Human Platelet Lysate Market: PMRs study on the global human platelet lysate market provides an exhaustive analysis of the market set for steady during 2019-2029. The study also elaborates on a detailed evaluation of key forces influencing growth in the market, major revenue strategies and key market players with their winning market strategies.

Autogenous Vaccines Market: Get vital information on the global autogenous vaccines market with segment-based analysis, major market statistics, and key growth factors, prominent market players and key marketing strategies adopted by them for a period under projection.

Gain access to Market Ngage, an AI-powered, real-time business intelligence platform that goes beyond the conventional research solutions to solve the complex strategy challenges that organizations face today.

About the ReportPersistence Market Research's market research study on the recombinant cell culture supplements market contains a global analysis of the market through20142018and provides growth assessment for20192029. The study offers insightful details of the hydrogen market through four major segments delivery mode, end-use, production method, and region.

About Persistence Market Research

Persistence Market Research (PMR) is an innovative and specialized supplier ofmarket intelligence reportsandconsulting services. Prompt delivery, in-depth research, and high quality are the sacrosanct principles of PMR. The companys research capabilities cover 5 continents, 1500+ reports, and 8 next-gen vertical expertise that have been catering to research demands of 5000+ clients.

Contact:

Rajendra Singh

Persistence Market Research

U.S. Sales Office:

305 Broadway, 7th Floor

New York City, NY 10007

+1-646-568-7751

United States

USA - Canada Toll-Free: 800-961-0353

For Sales Enquiries: sales@persistencemarketresearch.com

For Media Enquiries: media@persistencemarketresearch.com

Research Report: https://www.persistencemarketresearch.com/market-research/recombinant-cell-culture-supplements-market.asp

Press Release Source: https://www.persistencemarketresearch.com/mediarelease/recombinant-cell-culture-supplements-market.asp

See original here:
Recombinant Cell Culture Supplements Receive a Boost from Stem Cell Research Ventures; Demand for Novel Vaccines to Act as a Growth Lever, Says PMR -...

GOLDEN, CO / ACCESSWIRE / March 26, 2020 / Vitro Diagnostics, Inc. (VODG), dba Vitro Biopharma, announced its 1st quarter ended January 31st, 2020 financial results of operations.

Vitro Diagnostics Inc. ("Vitro Biopharma") is pleased to announce a record 1st comparative quarter in Total Revenues. Vitro Biopharma recorded 1st quarter revenues of $225,921 vs $192,895 an increase of 17% over the same comparative quarter last year. In addition, Stem Cell treatments accounted for 74% of the revenues up from 71% of the revenues in the prior comparative quarter last year. Current quarter stem cell revenues were $167,750 for the 1st quarter ended January 31, 2020 vs $137,123 for the first quarter ended January 31, 2019.

The company's gross profit margins improved to 75% up from 73% in the comparative prior year's quarter. Gross margin improvement is in line with the strategic direction of the company to expand the market of its flagship product AlloRx Stem Cells. The company's clean-room lab expansion last year and expanded Stem Cell manufacturing using its patent-pending cell line, has increased efficiencies and lowered production costs.

Overall operating expenses increased in the quarter to $193,385 from $147,398 in the prior year's comparative quarter. The increase in expenses reflects additional investment as the Company expands its capability to service its strategic direction of offshore Stem Cell treatments while also expanding into US markets. The company expended additional resources on external consultants supporting our regulatory status in maintaining ISO9001 & ISO13485 certifications, expanding our efforts to approach US markets through FDA filings and advancement of existing patent filings.

The company's first quarter is its most seasonal quarter as the period between Thanksgiving and the New Year is slow for all the company's revenue lines of Nutra Vivo/STEMulize, AlloRx Stem Cells, private labeled InfiniVive-MD Stem Cell Serum and our core research products.

During the quarter the company achieved and pursed the following company objectives

During the quarter the company commenced a Series A Convertible Preferred Stock offering to accredited investors under the SEC Regulation D exemption. The preferred Stock is priced at $25 per share which is convertible at $0.25 cents per share for a total of 100 shares. The minimum investment is $50,000 per unit. The company sold $450,000 of the Series A Convertible Preferred Stock during the quarter. The company has additional interest in the offering and subsequent to the quarter has sold an additional $50,000 unit for a total to date of $500,000. The company has additional interested parties for approximately $200,000. The offering is for a total of $1,000,000.

Our partnership with DVC. Stem in the Cayman Islands continued to advance through treatment of new & previous patients. This IRB-approved protocol targets patients with inflammatory conditions including multiple sclerosis, systemic inflammation and new indications including Chrohn's disease, Alzheimer's disease and COPD. To date we have treated 60 patients including repeat treatments. There have been no serious adverse events and we continue to gain evidence of efficacy. One of the initial MS patients has now received a second transplant of our AlloRx Stem Cells and he has reported significant therapeutic benefits of both the initial and subsequent therapy. He had received an earlier transplant of adipose-derived MSCs that was effective, but the improvement lasted 3 months while AlloRx Stem Cell therapy lasted 18 months. We had predicted such a clinical outcome based on significantly higher potency of umbilical cord MSCS compared to those derived from adipose tissue or bone marrow. The Chrohn's disease patient showed significant improvement as did both the AD & COPD patients.

The strategic development of our stem cell therapies involves pursuit of both offshore and domestic markets. The partnership with DVC Stem, our IRB-approved trial in the Bahamas together with other strategic opportunities represent offshore operations & prospects. During Q1 2020, we initiated expansion into US therapeutic markets through development of an Investigational New Drug (IND) application for submission to FDA. Once approved, an IND allows the conduct of clinical trials for specific medical conditions in the US.

Story continues

Given the current COVID-19 pandemic, our initial IND application is for use of AlloRx Stem Cells in treatment of Coronavirus infections. This is supported by clinical studies showing that 17 critically ill patients responded favorably to IV infusion of umbilical cord-derived MSCs. All patients were receiving assisted ventilation but 3 days following stem cell therapy, were removed from ventilators and subsequently discharged from the hospital. We are pursuing discussions with FDA to establish the appropriate regulatory pathway and expedited review options given the current emergency circumstances. (See Subsequent Events, below, for additional discussion of our COVID-19 response.) Once our initial IND is in place, we have plans for additional INDs for stem cell therapy of musculoskeletal conditions and Alzheimer's disease.

We have received an initial order of AlloRx Stem Cells for testing purposes by PR Medica located in Cabo San Lucas. Given successful test results, we anticipate subsequent new revenue generation from this customer.

Vitro Biopharma's cosmetic topical stem cell serum is being distributed by InfiniVive MD into cosmetic clinics that are providing the topical treatment as a beautification product. To date the company's product is being offered in 10 cosmetic clinics.

Our partner, Dr Jack Zamora, MD was a keynote speaker at a master session at the American Academy of Cosmetic Surgery annual meeting in late February. The topic of his presentation was "Topical Stem Cells, Exosomes and Conditioned Media Serums in Aesthetics." This was the official launch of the InfiniVive-MD platform including: Dailey Serum, Stem Cell Serum 2.0 & Exosomes within the product line. Vitro Biopharma will manufacture & private label these new products for distribution in the US. We anticipate InfiniVive MD growth, development and revenues to mirror the development of Apyx subdermal plasma skin tightening as a cosmetic treatment and technique that has gone global.

http://www.jackzamoramd.com http://www.infinivivemd.com

Our core research product sales continued to expand in Q1 2020. Our facility expansion continued with addition of manufacturing capacity and development of plans to add operational facility to increase outputs further by 100% or more. We were also in discussions with the USPTO regarding our pending patents for our novel stem cell therapy and stem cell activation technology. We continue to work closely with our examiner and have established communication channels to facilitate awards of these patents.

The COVD-19 pandemic is a significant obstacle for all business. However, Vitro Biopharma is uniquely positioned since we have a potential effective therapy. This is based on 3 independent reports showing efficacy of stem cell therapy in 17 COVID-19 patients. All were treated with IV umbilical cord MSCs comparable to AlloRx Stem Cells and all 17 required respiratory assistance but within 3-4 days of treatment, were able to breath without ventilators and were discharged within 14 days. https://www.scmp.com/news/china/society/article/3053080/coronavirus-critically-ill-chinese-patient-saved-stem-cell On the contrary, untreated patients on ventilators have death rates of 50% or more. We have received a formal request to supply AlloRx Stem Cells for compassionate use from a major university medical center and several other potential clinical partners have also expressed interest in using our cells to treat COVID-19 patients. We are presently working with the FDA to gain authority to begin clinical testing in the US. We are currently assessing the overall financial impact of the COVID-19 pandemic on our business, but this depends on overall control of the pandemic. There have been no staff layoffs and our workers are considered essential since we conduct essential research to the COVID-19 response.

Dr. Jim Musick, CEO of Vitro Biopharma, said, "We are very pleased with the increased revenue growth during our first quarter 2020 compared to the prior year However all our resources are currently focused on the emergency response to the COVID-19 pandemic and increasing our inventory of AlloRx to satisfy anticipated emergency demand to treat critically ill COVID-19 patients." The Company is working to get expedited clinical trial approvals to sell our AlloRx Stem Cells to hospitals coping with the pandemic. Vitro is pleased to have recently been recognized by Bioinformant as "a Company Tracking the Coronavirus". https://bioinformant.com/product/coronavirus-covid-19-report/ We anticipate clinical progress in the effectiveness of our stem cell therapies while expecting to see a reduction in our offshore and cosmetic revenues for the next quarter or two. The company is in a good cash position to weather this storm and simultaneously advance its AlloRx stem cell therapies into clinical trials.

In summary, Vitro Biopharma is advancing as a key player in regenerative medicine with 10- years' experience in the development and commercialization of stem cell products for research, recognized by a Best in Practice Technology Innovation Leadership award for Stem Cell Tools and Technology and a growing track record of successful translation to therapy. We are leveraging our proprietary technology platform to the establishment of international Stem Cell Centers of Excellence and regulatory approvals in the US and worldwide.

Sincerely yours,

James R. Musick, PhD.President, CEO & Chairman of the Boardwww.vitrobiopharma.com

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company's auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements". Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Dr. James MusickChief Executive OfficerVitro BioPharma(303) 999-2130 Ext. 3E-mail: jim@vitrobiopharma.comwww.vitrobiopharma.com

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.

SOURCE: Vitro Diagnostics, Inc.

View source version on accesswire.com: https://www.accesswire.com/582759/Vitro-Biopharma-First-Quarter-ended-January-31-2020-Financial-Results-of-Operations

Read more:
Vitro Biopharma First Quarter ended January 31, 2020 Financial Results of Operations - Yahoo Finance

Washington University School of Medicinein St. Louis released a newstudyabout the effectiveness of immunotherapy based on the age of the cells used. The study, published in the journalDevelopmental Cell,showed that these natural killer cells seem to be more effective when they are young. Natural killer (NK) cells, as they're called, are used in immunotherapy to treat cancer using the body's immune cells or immune cells from a matched donor.

"We are trying to improve the effectiveness of immunotherapy for more patients," said senior author Christopher M. Sturgeon, Ph.D., an assistant professor of medicine.

Typically, NK cells used in investigational immunotherapy are adult and come from the patient or donor bone marrow. While these therapies can work, they don't work for everyone.

In contrast, young NK cells do not use the patient's cell or donor cells. These early NK cells, typically formed in the yolk sac in the early embryo, are instead able to be created with human pluripotent stem cells. They can be manufactured quickly by most academic medical centers, thus eliminating the time it takes to process patient's or donor's cells for typical NK cell therapy.

"This special source of natural killer cells has the potential to fill some of the gaps remaining with adult NK cell therapy. There is early evidence that they are more consistent in their effectiveness, and we would not need to process cells from a donor or the patient. They could be manufactured from existing cell supplies following the strict federal guidelines for good manufacturing practices. The characteristics of these cells let us envision a supply of them ready to pull off the shelf whenever a patient needs them," Sturgeon said.

Instudieswith mice using the lab-developed human pluripotent stem cells to create early NK cells, researchers found positive results. These cells were significantly better at degranulation than adult NK cells. Even cells from umbilical cord blood did not respond as well as the early NK cells. Additionally, early NK cells are a particular type of short-lived immune cell, meaning that even if the cells cause harm, they aren't in the body for very long. However, NK cells, in general, do not attack the body's healthy tissues significantly, unlike many T cell therapies.

"Based on their unique behavior alone, there is one small clinical trial of these cells that is ongoing. Now that we know how to manufacture them and how they work, it opens the door for more trials and for improving upon their function, " Sturgeon said.

More research will need to be put into understanding why these special cells only show up in the early embryo and where they go after.

The origin and why they work so well is still a complete mystery.

"We can only speculate at this point, but it's possible that during early embryonic development, when there is so much rapid cell division, these cells are there as a surveillance mechanism to protect against pediatric cancers or infection," he said.

In addition to the early NK cells, pluripotent stem cells also have the potential to bring about many other different cell types, creating more possibilities.

Here is the original post:
Study Shows Development of Young Cells Could be New Option in Cancer Care - BioSpace

The positioning of the Global Cell Expansion Market vendors in FPNV Positioning Matrix are determined by Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinders, N: Niche, and V: Vital).

New York, March 25, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cell Expansion Market - Premium Insight, Competitive News Feed Analysis, Company Usability Profiles, Market Sizing & Forecasts to 2025" - https://www.reportlinker.com/p05872140/?utm_source=GNW

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cell Expansion Market including are Beckman Coulter Inc., Becton, Dickinson and Company, Merck KGaA, Terumo BCT, Thermo Fisher Scientific, Inc., Corning Incorporated, GE Healthcare, Lonza Group LTD., Miltenyi Biotec, Promocell GmbH, Sartorius AG, Stemcell Technologies, Inc., and Takara Bio Inc..

On the basis of Product, the Global Cell Expansion Market is studied across Consumables and Instruments.

On the basis of Cell Type, the Global Cell Expansion Market is studied across Animal Cells and Human Cells.

On the basis of Application, the Global Cell Expansion Market is studied across Cancer and Cell-Based Research and Regenerative Medicine and Stem Cell Research.

On the basis of End User, the Global Cell Expansion Market is studied across Biotechnology & Biopharmaceutical Companies, Cell Banks, and Research Institutes.

For the detailed coverage of the study, the market has been geographically divided into the Americas, Asia-Pacific, and Europe, Middle East & Africa. The report provides details of qualitative and quantitative insights about the major countries in the region and taps the major regional developments in detail.

In the report, we have covered two proprietary models, the FPNV Positioning Matrix and Competitive Strategic Window. The FPNV Positioning Matrix analyses the competitive market place for the players in terms of product satisfaction and business strategy they adopt to sustain in the market. The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisitions strategies, geography expansion, research & development, new product introduction strategies to execute further business expansion and growth.

Research Methodology:Our market forecasting is based on a market model derived from market connectivity, dynamics, and identified influential factors around which assumptions about the market are made. These assumptions are enlightened by fact-bases, put by primary and secondary research instruments, regressive analysis and an extensive connect with industry people. Market forecasting derived from in-depth understanding attained from future market spending patterns provides quantified insight to support your decision-making process. The interview is recorded, and the information gathered in put on the drawing board with the information collected through secondary research.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on sulfuric acid offered by the key players in the Global Cell Expansion Market 2. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments in the Global Cell Expansion Market 3. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets for the Global Cell Expansion Market 4. Market Diversification: Provides detailed information about new products launches, untapped geographies, recent developments, and investments in the Global Cell Expansion Market 5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players in the Global Cell Expansion Market

The report answers questions such as:1. What is the market size of Cell Expansion market in the Global?2. What are the factors that affect the growth in the Global Cell Expansion Market over the forecast period?3. What is the competitive position in the Global Cell Expansion Market?4. Which are the best product areas to be invested in over the forecast period in the Global Cell Expansion Market?5. What are the opportunities in the Global Cell Expansion Market?6. What are the modes of entering the Global Cell Expansion Market?Read the full report: https://www.reportlinker.com/p05872140/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Here is the original post:
The Global Cell Expansion Market is expected to grow from USD 11,923.12 Million in 2018 to USD 30,023.12 Million by the end of 2025 at a Compound...

(The Center Square) California is under a shelter-in-place order due to the coronavirus pandemic, but several ballot initiative campaigns are in the final days or weeks of their signature drives. As of March 23, four citizen-initiated measures have qualified to appear on the ballot in November. An additional nine ballot initiatives could receive enough signatures to appear on the ballot.

The deadline for signature verification is June 25, 2020. However, the process of verifying signatures can take multiple months. Secretary of State Alex Padilla (D) recommends that campaigns file signatures no later than April 21. Campaigns that file signatures after the deadline can still have their proposals appear on the ballot for November 8, 2022.

Gov. Gavin Newsom (D) has directed residents to remain at home, except as needed for food, medicine, and other services deemed essential, due to the pandemic. The California Department of Health has advised that non-essential gatherings be postponed or canceled, and the CDC is recommending that people maintain distance between each other.

Jamie Court, president of Consumer Watchdog, stated, We were getting 70,000 signatures a week until a couple of weeks ago, when it almost stopped. According to Fred Kimball, owner of the signature-gathering firm Kimball Petition Management, Were all flying by the seat of our pants. No one has ever seen this.

Campaigns behind the following nine citizen-initiated measures are seeking a place for their proposals on the general election ballot. Coronavirus, however, could have the effect of limiting the number of signatures that an individual petitioner can collect, especially for campaigns that didnt launch until January 2020.

Property Tax Transfers and Exemptions Initiative (#19-0003): The campaign Homeownership for Families and Tax Savings for Seniors filed 1.43 million signatures on March 4. At least 997,139 signatures need to be valid. The ballot measure would change how tax assessments are transferred between properties for eligible homebuyers and address resetting tax assessments to fair market value on inherited properties and when corporations and other entities acquire control of properties. Homeownership for Families and Tax Savings for Seniors, which is associated with the California Association of Realtors, has raised $12.08 million.

Tax on Commercial and Industrial Properties for Education and Local Government Funding Initiative (#19-0008): An earlier version of the citizen-initiated measure has qualified for the ballot, but the campaign Schools and Communities First is seeking to replace the initiative with an amended version. The campaign needs to file at least 997,139 valid signatures. Schools and Communities First has raised $17.13 million. Both versions of the ballot initiative would amend the state constitution to require commercial and industrial properties, except those zoned as commercial agriculture, to be taxed based on their market value.

Consumer Personal Information Law and Agency Initiative (#19-0021): The ballot initiative seeks to expand the provisions of the California Consumer Privacy Act (CCPA), which was passed in 2018. The campaign Californians for Consumer Privacy raised $3.42 million for this years effort. Robin Swanson, a consultant for the campaign, said, Were in pretty good shape with the numbers that we have, but are adhering to public health requirements and putting public safety first. Like most ballot measure campaigns out there, wed always love more signatures, but were dealing with a stark new reality while the state is on lockdown. At least 623,212 valid signatures need to be filed for the ballot measure.

Stem Cell Research Institute Bond Initiative (#19-0022): Californians for Stem Cell Research, Treatments, and Cures is backing a ballot initiative to issue $5.5 billion in general obligation bonds for the state's stem cell research institute. Spokesperson Sarah Melbostad said the campaigns signature drive has been suspended due to the coronavirus pandemic. "In keeping with the governors statewide order for non-essential businesses to close and residents to remain at home, weve suspended all signature gathering for the time being. ... Were confident that we still have time to qualify and plan to proceed accordingly, said Melbostad. Proponents have raised $5.28 million. The campaign needs to collect at least 623,212 valid signatures.

Dialysis Clinic Requirements and Consent to Close Initiative (#19-0025): Californians for Kidney Dialysis Patient Protection, which backed a defeated dialysis-related initiative in 2018, has raised $5.38 million for the new effort. The campaign needs at least 623,212 valid signatures.

App-Based Drivers Regulations Initiative (#19-0026): With $110.58 million, Protect App-Based Drivers and Services has collected over 1 million signatures, of which 623,212 need to be valid. The campaign has the support of Uber, Lyft, Doordash, Instacart, and Postmates. The ballot measure would consider app-based drivers to be independent contractors and enact several wage and labor policies that would affect app-based drivers and companies. Spokesperson Stacy Wells said, We were really lucky. We got our signatures in fast and were able to get off the streets in seven weeks.

Packaging Waste Reduction Regulations Initiative (#19-0028): The ballot measure would require CalRecycle, in consultation with other agencies, to adopt regulations that reduce the use of product packaging, single-use packaging, and single-use dishes and utensils. The campaign Clean Coasts, Clean Water, Clean Streets has raised $3.26 million. At least 623,212 valid signatures need to be collected.

Legalize Sports Betting on American Indian Lands Initiative (#19-0029): The Coalition to Authorize Regulated Sports Wagering, with the support of several tribal governments, has raised $7.5 million for a ballot measure to legalize sports betting at American Indian gaming casinos and licensed racetracks. The effort to collect 997,139 valid signatures began on January 21, 2020. We are at nearly 1 million signatures and were on a trajectory to reach our goal well ahead of the deadline before the unprecedented orders around COVID-19, said Jacob Mejia, a spokesperson for the campaign. He added, The health and well-being of Californians is foremost. Thus, paid signature-gathering efforts have paused for the time being.

More here:
California ballot initiative campaigns are in the final weeks of their signature drives and face the effects of coronavirus - The Center Square